Recently, B.-H. Choi et al. characterized a novel anti-mitotic molecule termed suprafenacine which destabilizes microtubules, resulting in cell cycle arrest in the G2/M phase and apoptotic cell death. In silico screening identified several novel anti-cancer molecules based on their ability to inhibit in vitro cell proliferation and tubulin polymerization. Structure Activity Relationship studies guided the synthesis of several analogues. Of these analogues, suprafenacine was the most potent based on its in vitro ability to 1. specifically target cancer cells from multiple tumor types and 2. inhibit tubulin polymerization (IC50 = 0.38 mM).
If you are working on Genomics and are looking for a post-doc position, you may be interested to know that CNAG in Barcelona is recruiting.
The CNAG has a park of twelve second generation DNA sequencers supported by an extensive informatics infrastructure, and is one of the major Genome Sequencing Centers in Europe. It participates in quite a number of consortia of networked projects and EU-funded projects.
The candidate needs to have a strong background in bioinformatics. The position is open at the Structural Genomics Team, CNAG and CRG.
You can find more information here, interested candidates may submit a CV, a brief statement of interests and two letters of reference from previous advisers before February 28th 2015 to Marc A. Marti-Renom at (mmarti @ pcb.ub.cat).
PS. For football fans, this institute is located very near to Camp Nou, the home stadium for F.C. Barcelona!